Company News

Company News
September 30, 2022
Core One Labs Announces Breakthrough with Proprietary Isolation and Purification Method of Psilocybin from Mushrooms; Prepares Patent Application
Vancouver, British Columbia, Canada – September 30, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
September 23, 2022
Core One Labs Signs Letter of Intent with GMP Manufacturing Partner for Production of Proprietary Psychedelic Compounds
Vancouver, British Columbia, Canada – September 23, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
September 16, 2022
Core One Labs’ Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential
Vancouver, British Columbia, Canada – September 16, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
September 02, 2022
Core One Labs’ Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT
Second Ground Breaking Technological Advancement   Vancouver, British Columbia, Canada – September 2, 2022 – Core One Labs Inc. (CSE: COOL),...
Read more
Company News
September 01, 2022
Core One Rolls Out Commercial Sales Strategy for its Revolutionary API Grade Biosynthetic Psilocybin
Vancouver, British Columbia, Canada – September 1 2022 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
August 30, 2022
Core One Labs Applauds New Study Supporting Psilocybin Psychedelic Drug Therapy May Help Treat Alcohol Addiction
Vancouver, British Columbia, Canada - August 30, 2022 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (FWB: LD6,...
Read more